...and Indian rights to Beleodaq, a small molecule histone deacetylase inhibitor. BioAlliance Pharma S.A. and Topotarget A/S...

...combination with chlorambucil for first-line CLL in patients unsuitable for fludarabine-based therapy Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)/Topotarget A/S...

...Cancer companies BioAlliance and Topotarget completed their merger in a stock deal. The new company is...
...stock deal. The new company is Onxeo S.A. (Euronext:ONXEO, Paris, France) (see BioCentury, April 21). Topotarget A/S...

...rights to the mucoadhesive formulation of acyclovir from Onxeo. Last month, BioAlliance S.A. merged with Topotarget A/S...

...regulatory milestone payments. The companies could not be reached for details. BioAlliance is merging with Topotarget A/S...

...Business: Cancer Resigning: Anders Vadsholt as CEO, effective July 31 or until the approval of Topotarget’s...

...payment to partner Topotarget A/S (CSE:TOPO). Spectrum has North American and Indian rights to belinostat from Topotarget...
...company BioAlliance Pharma S.A. (Euronext:BIO). Spectrum finished Independence Day week up $0.89 (11%) to $8.90. Topotarget...

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget...
...America and India. The approval triggered a $25 million milestone payment to Topotarget from Spectrum. Topotarget...
...is a small molecule dihydrofolate reductase (DHFR) inhibitor. Spectrum Pharmaceuticals Inc . (NASDAQ:SPPI), Henderson, Nev. Topotarget A/S...

...said details of the trial design have yet to be determined. Spectrum has rights from Topotarget A/S...
...million milestone payment to Topotarget from Spectrum. Spectrum was up $0.18 to $8.90 on Thursday. Topotarget...